InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,499.45
(
-0.41%
)
US TECH 100
18,790.40
(
-0.28%
)
Dow Jones
40,538.95
(
-0.74%
)
Brent Oil
80.50
(
-1.25%
)
Bitcoin
64,183.84
(
-0.66%
)
Post# of 252758
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120173
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 203056

Tuesday, 08/02/2016 3:01:01 PM

Tuesday, August 02, 2016 3:01:01 PM

Post# of 252758
ADXS CC is a good listen for highlighting the differences between the ADXS-NEO approach and cell-based cancer therapies. (ADXS-NEO extracts multiple antigens from a biopsy of a patient's tumor, but it does not extract whole cells.)

Amusingly, the sell-side analyst from Janney asked if ADXS's "double-digit" royalty rate from AMGN is as much as 50%. (The actual upper bound hasn't been disclosed.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up